FLAME 30
176 Reports in Pharmaceuticals
Markets at a Glance: Pharmaceuticals
The “Market at a Glance Pharmaceuticals” provides an access to all the market share analysis segments of the best-selling and key pharmaceutical reports of BCC Research. This report is a destination for the competitive landscape in the markets that hold a significant stand in the pharmaceuticals sector. Company profiles for all the notable manufacturers in the global pharmaceutical industry are provided as a part of this report.
Nothing Degrading about Saving Lives: E3 Ligands Recruiting New D...
Posttranslational modifications hit prime time in the pharma industry. There probably isn’t a medium sized biopharmaceutical that does not have an active program ongoing, and certainly all of the big pharma companies are running multiple programs, and collaborations, for what we might have previously termed “undruggable targets”. Many of these are for highly unmet needs in neurodegeneration. The properties of the structure that forms between a target, a degrader and an E3 ligase, are under intense investigation. Minor changes affect how the drugs work - this can explain how promiscuous target-binding payloads can achieve super selectivity when transformed into a degrader. These minor alterations can also render the molecule complex not only ineffective, but sometimes toxic. However, clinical results are beginning to write a compellingly effective story – the long and winding history of research into the ubiquitin proteasome may well have more blockbusters in store for us. And cures in a once overlooked corner of the cell machinery architecture.
Colorectal Cancer Therapeutics: Global Markets
The global colorectal cancer therapeutics market should reach $18.5 billion by 2023 from $13.7 billion in 2018 at a compound annual growth rate (CAGR) of 6.1% for the period 2018 to 2023.
Drugs of Abuse Testing: Technologies and Global Markets
The global market for drugs of abuse (DOA) testing should grow from $3.5 billion in 2018 to $4.6 billion by 2023 with a compound annual growth rate (CAGR) of 5.6% for the period of 2018-2023.
Laboratory Animal Models, 3D Cultures and Organoids
The global market for laboratory animal models should grow from $5.9 billion in 2018 to $7.8 billion by 2023, increasing at a compound annual growth rate (CAGR) of 5.6% for the period of 2018-2023.
2018 Pharmaceuticals Research Review
2018 Pharmaceuticals Research Review provides a sampling of the type of quantitative market information, analysis and guidance that has been aiding business decision making.
Laboratory Automation Systems and Processes: Global Markets and T...
The global market for laboratory automation systems and processes should grow from $21.1 billion in 2018 to reach $29.2 billion by 2023 at a compound annual growth rate (CAGR) of 6.8% for the period of 2018-2023.
In Vitro Toxicity Testing: Technologies and Global Markets
The global market for in vitro toxicity testing should grow from $7.4 billion in 2018 to reach $10.4 billion by 2023 at a compound annual growth rate (CAGR) of 7.1% for the period of 2018-2023.
High-Throughput Screening: Technologies and Global Markets
The global high-throughput screening (HTS) market should reach $21.1 billion by 2023 from $14.4 billion in 2018 at a compound annual growth rate (CAGR) of 7.9% for the period 2018-2023.
Blood Cancer Therapeutics: Global Markets to 2023
The global market for blood cancer therapeutics should grow from $38.5 billion in 2018 to $64.8 billion by 2023 at a compound annual growth rate (CAGR) of 11.0% from 2018 to 2023.
Brain Tumor Therapeutics: Global Markets to 2023
The global market for brain tumor therapeutics should grow from $1.1 billion in 2018 to reach $2.0 billion by 2023 at a compound annual growth rate (CAGR) of 12.9% for the period of 2018-2023.
Global Cancer Therapeutics Market: Emphasis on Recurrent and Meta...
The global cancer therapeutics market should grow from $128.1 billion in 2018 to $182.0 billion by 2023 at a compound annual growth rate (CAGR) of 7.3% for the period of 2018-2023.
Global Market for Contract Research Organization (CRO) Services
The global market for CRO's across the clinical trial process should grow from $45.5 billion in 2017 to reach $72.3 billion by 2022 at a compound annual growth rate (CAGR) of 9.7% for the period of 2017-2022.
Opioid Drugs: Global Markets to 2023
The global market for opioid drugs should reach $29.8 billion by 2023 from $26.4 billion in 2018 at a compound annual growth rate (CAGR) of 2.5% for the period of 2018-2023.
Antibiotics: Global Markets to 2023
The global antibiotics market should reach $55.8 billion by 2023 from $38.3 billion in 2018 at a compound annual growth rate (CAGR) of 7.8% for the period of 2018-2023.
Lung Cancer Therapeutics: Global Markets
The global market for lung cancer therapeutics should grow from $17.9 billion in 2018 to $26.3 billion by 2023, increasing at a compound annual growth rate (CAGR) of 8.0% from 2018 to 2023.
Diagnostics and Therapeutics for HIV: Global Markets
The global HIV therapeutics market should reach $27.1 billion by 2023 from $22.0 billion in 2018 at a compound annual growth rate (CAGR) of 4.3% for the period of 2018 to 2023.
Checkpoint Inhibitors: Global Markets
The global checkpoint inhibitors market should reach $29.3 billion by 2023 from $14.9 billion in 2018 at a compound annual growth rate (CAGR) of 14.4% for the period of 2018-2023.
Global Viral Vector Manufacturing Markets and Technologies Throug...
The global market for viral vector vaccine manufacturing is expected to increase from $22.9 million in 2017 to nearly $51.2 million in 2022 at a compound annual growth rate (CAGR) of 17.5% for 2017-2022.
Antipsychotic Drugs: Technologies and Global Markets
The global market for antipsychotic drugs should grow from $13.2 billion in 2018 to reach $14.5 billion by 2023 at a compound annual growth rate (CAGR) of 1.9% for the period of 2018-2023.
Lysosomal Disease Treatments: Technologies and Global Markets
The global market for lysosomal storage diseases treatment should grow from $5.1 billion in 2018 to reach $7.6 billion by 2023 at a compound annual growth rate (CAGR) of 8.3% for the period of 2018-2023.
Global Markets for Treatment and Diagnosis of Sexually Transmitte...
The global market for sexually transmitted disease therapeutics reached $52.0 billion in 2018 and should reach nearly $63.0 billion by 2023, at a compound annual growth rate (CAGR) of 3.9% for the period of 2018-2023.
Antiemetics: Technologies and Global Markets
The global market for antiemetics reached $4.1 billion in 2017 and should reach $5.9 billion by 2022, at a compound annual growth rate (CAGR) of 6.5% during the forecast period of 2018-2023.
Pharmaceuticals for Women's Health: Global Markets to 2023
The global market for women’s health therapeutics reached nearly $30.5 billion in 2018 and should reach nearly $37.3 billion by 2023, at a compound annual growth rate (CAGR) of 4.2% for the period of 2018-2023.
Cognition and Memory Enhancement Drugs: Technologies and Global M...
The global cognition and memory-enhancing drugs market should reach over $4.2 billion by 2022 from $2.8 billion in 2017 at a compound annual growth rate (CAGR) of 8.7% for the period 2017-2022.
Choose your License
6 Upcoming Reports in Pharmaceuticals
Interleukin-2, a Tale of Two Halves: To Suppress or Augment Suppression, That is the Question
Report Includes
- An introduction to interleukin-2 (IL-2) and identification of its applications
- Insights of the latest trends and technologies in the IL-2 research and development
- Discussion of strategies adopted by IL-2 developers for the successful treatment of cancer and information on NKTR-214, a Nektar Therapeutics product
- Review of recent VC investment in this zone highlighted by Syncona and Novartis Venture Fund recent CHF35m investment in Anaveon AG, a new Swiss Biotech company spun out from the University of Zuirich which is developing a novel oncologic monoclonal antibody that boosts IL-2 but has an improved side-effect profile.
- Detailed description of autoimmune responses and possible ways to augment immune responses so as to improve antitumor activity and reduce off target effect
- An understanding of various conditions which may develop as an off-target effects in the cancer treatment such as metastatic melanoma (MM), renal cell carcinoma (RCC), urothelial cancers (US) relapse remitting multiple sclerosis (RRMS), and Type 1 diabetes (T1D)
